Loading...

Clincial Study Patient Recruitment and Site Engagement

Liver Cirrhosis

Stark Raving Branding and Digital Marketing

Red-C: A Clinical Study for the prevention of complications in Patients with Liver Cirrhosis

SponsorBausch

 

SponsorPRA Health Sciences

 

IndicationLiver Cirrhosis

 

MaterialsStudy Branding

 Patient Outreach

 Patient Education

 Site Staff Materials

 Referring Physician

 Patient Retention






The RED-C Study was a randomized, double-blind, placebo-controlled, dose-ranging, multicenter study to assess the efficacy and safety of rifaximin soluble solid dispersion (SSD) tablets for the prevention of complications in patients with early decompensated liver cirrhosis.

The primary objective of this study was to assess the efficacy of rifaximin SSD versus placebo in preventing complications of liver cirrhosis, such as death due to all causes or hospitalization, in subjects with early decompensated liver cirrhosis. Rifaximin, a non-systemic antibacterial agent, is currently marketed as a 550 mg tablet for the reduction in risk of recurrent overt hepatic encephalopathy, a complication of liver cirrhosis. The rifaximin SSD tablet was formulated to maximize the efficacy of rifaximin. Study participants received 1 of 5 doses of rifaximin SSD tablets or placebo tablets every day for 24 weeks.






Stark Raving Branding and Digital Marketing

Let's talk about your next project
To discuss an upcoming project or to learn more about our services, please contact us.

Be sure you complete all fields. Thank you!